冷冻干燥注射剂市场－全球产业规模、份额、趋势、机会与预测：包装、剂量、适应症、终端用户、地区和竞争格局，2021-2031年

全球冷冻干燥注射剂市场预计将从 2025 年的 33.7 亿美元成长到 2031 年的 58.5 亿美元，复合年增长率为 9.63%。

冷冻干燥注射剂是一种冷冻干燥製剂，可透过去除水分来提高对温度敏感的生物製药的稳定性并延长其保质期。市场成长趋势主要受以下因素驱动：全球范围内需要生物製剂治疗的慢性疾病发生率不断上升，以及药品分销网络对长期储存能力的迫切需求。此外，越来越多的复杂分子在液态下稳定性较差，也迫使生产商采用冷冻干燥技术来确保药物在运输过程中的效力。

然而，该市场面临许多挑战，包括生产流程复杂和供应链不稳定，这常常导致严重的药品短缺。无菌生产设施所需的大量资本投入以及对监管标准的严格遵守进一步限制了产能。根据美国药典（USP）2024年的数据，无菌注射剂占所有活性成分短缺的69%。这一数字凸显了生产基础设施的严重不足，并对全球市场的稳定成长构成了重大障碍。

市场驱动因素

生物製药和复杂大分子疗法的快速发展是市场成长的关键驱动力。随着製药创新者日益重视单株抗体和胜肽等大分子药物，这些液体製剂固有的不稳定性使得冷冻干燥技术的应用成为维持其长期疗效的必要手段。这些治疗方法获得监管部门核准的数量持续增长，也印证了这一发展势头。例如，BioPharma PEG在2025年1月报道称，FDA在2024年核准了18种新的生物製药，这在通常需要先进冻干技术的创新治疗方法中占有相当大的比例。此外，业界对专科治疗的日益关注也推动了这一转变。监管事务专业人员协会（RAPS）在2025年1月指出，2024年新药认证中有52%用于治疗罕见疾病，而罕见疾病领域高度依赖稳定的冷冻干燥注射剂进行全球分销。

同时，合约研发生产机构（CDMO）服务的成长正在改变製药业的格局。由于无菌冻干製程需要大量的资金投入和技术挑战，创新企业越来越多地将生产外包给专业合作伙伴，而这些合作伙伴也正在积极扩建设施以避免产能瓶颈。根据DCAT价值链洞察2025年7月发布的报告，Better Pharma已在伊利诺伊州德斯普兰斯市启动了一座价值2.85亿美元的新临床生产设施的建设，以确保复杂注射剂的长期供应。这项增加的外部生产投资满足了对适应性强、扩充性的供应链的迫切需求，直接缓解了无菌注射剂生产基础设施长期以来的脆弱性。

市场挑战

生产流程的高度复杂性和供应链固有的脆弱性是限制全球冷冻干燥注射剂市场发展的主要障碍。建立无菌生产环境需要大量的资金投入和严格遵守监管通讯协定，这限制了合格生产商的数量。生产能力的集中化意味着，即使单一工厂出现轻微的技术问题或品质保证失误，也可能导致大范围的产品供不应求。这种缺乏营运柔软性限制了该行业快速调整产量以应对需求波动的能力。

反覆出现的供应中断直接降低了市场收入，并阻碍了冷冻干燥疗法的广泛应用。持续无法维持可靠的库存水准迫使医疗机构限制供应或转向其他製剂。根据美国医疗保健系统药剂师协会 (ASHP) 统计，2024 年第一季，製药业的药品短缺数量达到创纪录的 323 种。这种前所未有的供应链不稳定性凸显了製造商在满足全球需求方面所面临的挑战，并严重阻碍因素了市场实现可持续的财务成长。

市场趋势

双腔注射器和药筒的广泛应用代表包装技术的重大进步，旨在缓解冷冻干燥产品復溶过程中遇到的难题。这些先进的系统将冷冻干燥粉末和稀释剂分别置于独立的腔室中，从而实现装置内的自动混合，避免了人为操作失误以及手动操作管瓶带来的污染风险。这种对以患者为中心的设计的日益重视也体现在关键组件製造商强劲的财务表现上。根据Stevanato集团于2025年3月发布的2024财年财务报告，其高价值解决方案部门（包括高性能注射器）的营收达到4.223亿欧元，较去年同期成长15%。

同时，人工智慧 (AI) 在循环优化中的应用正从根本上改变製造业的生产效率，它以预测模型取代了传统的试验法。製药工程师正利用人工智慧演算法数位双胞胎模拟来预测干燥过程，并即时追踪关键製程变量，从而在确保产品品质稳定的同时，显着缩短高能耗的生产週期。领先的生物製药公司正积极采用这些数位化工具来提升供应链的反应速度。例如，赛诺菲于 2025 年 5 月宣布推出第三个数位化加速器项目，致力于数位化。这些由人工智慧驱动的措施旨在将新药上市时间缩短至多一年。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球冻干注射剂市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依包装方式（一次性管瓶、照护现场復溶、特殊包装）
  • 依给药方式（预填充稀释剂注射器、专用复溶装置、一步式装置、多步骤装置）
  • 按适应症（自体免疫疾病、感染疾病、代谢性疾病、其他）
  • 依最终用户（医院药局、零售药局、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美冷冻干燥注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲冷冻干燥注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区冷冻干燥注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲冷冻干燥注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲冷冻干燥注射剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球冷冻干燥注射剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• B. Braun Melsungen AG
• Baxter International Inc.
• Becton, Dickinson and Company
• Schott AG
• Aristopharma Ltd.
• Vetter Pharma GmbH
• Jubilant HollisterStier LLC
• F. Hoffmann-La Roche Ltd
• Novo Nordisk A/S

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Lyophilized Injectable Market is projected to expand from USD 3.37 Billion in 2025 to USD 5.85 Billion by 2031, reflecting a CAGR of 9.63%. Lyophilized injectables consist of freeze-dried pharmaceutical formulations developed to improve the stability and extend the shelf life of temperature-sensitive biological products by eliminating moisture content. The market's upward trajectory is largely fueled by the growing global incidence of chronic conditions that require biologic treatments, alongside the essential need for prolonged storage capacities within pharmaceutical distribution networks. Furthermore, the rising creation of complex molecules that lack stability in liquid states forces producers to implement lyophilization techniques to guarantee efficacy during transportation.

Conversely, the market encounters substantial hurdles regarding production intricacy and supply chain instability, which frequently lead to severe product shortages. The necessity for significant capital expenditure on sterile manufacturing sites and strict adherence to regulatory standards further limits production potential. According to data from the U.S. Pharmacopeia in 2024, sterile injectable drugs accounted for 69% of all active drug shortages. This figure highlights the severe fragility of the manufacturing infrastructure, representing a significant barrier to the steady growth of the global market.

Market Driver

The swift expansion of biologics and complex macromolecule therapies acts as a major catalyst for market advancement. As pharmaceutical innovators increasingly prioritize large-molecule medications like monoclonal antibodies and peptides, the natural instability of these liquid formulations demands the application of lyophilization to maintain long-term potency. This momentum is supported by the consistent volume of regulatory approvals for such treatments; for instance, Biopharma PEG reported in January 2025 that the FDA authorized 18 new biologic entities in 2024, constituting a significant share of new therapies that usually necessitate sophisticated freeze-drying methods. This transition is further bolstered by the industry's emphasis on specialized medicine, with the Regulatory Affairs Professionals Society noting in January 2025 that 52% of new drug approvals in 2024 targeted rare diseases, a sector heavily dependent on stable, lyophilized injectable forms for worldwide distribution.

Simultaneously, the growth of Contract Development and Manufacturing Organization (CDMO) services is transforming the production environment. The substantial capital requirements and technical difficulties linked to sterile lyophilization are driving innovators to outsource production to specialized partners who are actively expanding their facilities to avoid capacity constraints. As reported by DCAT Value Chain Insights in July 2025, Vetter Pharma began construction on a new $285 million clinical manufacturing facility in Des Plaines, Illinois, aiming to ensure long-term availability for complex injectables. This increase in external manufacturing investment meets the urgent demand for adaptable and scalable supply chains, directly mitigating the historical vulnerability of the sterile injectable production base.

Market Challenge

The intense complexity of production processes and the inherent vulnerability of the supply chain serve as major obstacles to the advancement of the Global Lyophilized Injectable Market. Creating sterile manufacturing environments requires massive capital funding and rigorous compliance with regulatory protocols, which limits the pool of qualified manufacturers. This centralization of manufacturing capabilities implies that even slight technical issues or quality assurance failures at a single site can cause extensive product unavailability. Such operational inflexibility constrains the industry's capacity to rapidly adjust production levels in reaction to shifting demand.

These repeated supply disruptions directly diminish market earnings and impede the wider acceptance of lyophilized treatments. The ongoing failure to sustain dependable inventory levels compels healthcare networks to ration supplies or transition to substitute formulations. According to the American Society of Health-System Pharmacists, the pharmaceutical sector hit a record high of 323 active drug shortages in the first quarter of 2024. This unparalleled degree of supply chain volatility emphasizes the challenges manufacturers encounter in satisfying global requirements, thereby serving as a primary constraint on the market's consistent financial expansion.

Market Trends

The widespread adoption of dual-chamber syringes and cartridges marks a significant advancement in packaging technology, designed to alleviate the reconstitution difficulties associated with lyophilized products. These sophisticated systems separate the freeze-dried powder and the diluent into distinct chambers, enabling automatic mixing within the unit to eradicate user mistakes and contamination risks linked to manual vial manipulation. The increasing dependence on these patient-friendly designs is mirrored in the robust financial results of major component producers. As per the Stevanato Group's fiscal year 2024 results released in March 2025, revenue from their high-value solutions division, which comprises high-performance syringes, rose by 15% year-over-year to reach €422.3 million.

In parallel, the integration of Artificial Intelligence (AI) for cycle optimization is radically transforming manufacturing productivity by substituting empirical trial-and-error approaches with predictive modeling. Pharmaceutical engineers are utilizing AI algorithms and digital twin simulations to predict drying behaviors and track essential process variables in real-time, guaranteeing uniform product quality while significantly shortening energy-heavy cycle times. Prominent biopharmaceutical companies are actively adopting these digital tools to improve supply chain responsiveness. For example, Sanofi announced in May 2025 the launch of its third Digital Accelerator dedicated to digitizing its worldwide manufacturing and supply chain, aiming to cut the time to market for new drugs by as much as one year through these AI-powered initiatives.

Key Market Players

• B. Braun Melsungen AG
• Baxter International Inc.
• Becton, Dickinson and Company
• Schott AG
• Aristopharma Ltd.
• Vetter Pharma GmbH
• Jubilant HollisterStier LLC
• F. Hoffmann-La Roche Ltd
• Novo Nordisk A/S

Report Scope

In this report, the Global Lyophilized Injectable Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lyophilized Injectable Market, By Packaging

• Single-Use Vials
• Point-Of-Care Reconstitution
• Specialty Packaging

Lyophilized Injectable Market, By Delivery

• Prefilled Diluent Syringes
• Proprietary Reconstitution Devices
• Single-Step Devices
• Multi-Step Devices

Lyophilized Injectable Market, By Indication

• Autoimmune Diseases
• Infectious Diseases
• Metabolic Conditions
• Others

Lyophilized Injectable Market, By End-User

• Hospital Pharmacy
• Retail Pharmacy
• Others

Lyophilized Injectable Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lyophilized Injectable Market.

Available Customizations:

Global Lyophilized Injectable Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lyophilized Injectable Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Packaging (Single-Use Vials, Point-Of-Care Reconstitution, Specialty Packaging)
  • 5.2.2. By Delivery (Prefilled Diluent Syringes, Proprietary Reconstitution Devices, Single-Step Devices, Multi-Step Devices)
  • 5.2.3. By Indication (Autoimmune Diseases, Infectious Diseases, Metabolic Conditions, Others)
  • 5.2.4. By End-User (Hospital Pharmacy, Retail Pharmacy, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Lyophilized Injectable Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Packaging
  • 6.2.2. By Delivery
  • 6.2.3. By Indication
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lyophilized Injectable Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Packaging
      • 6.3.1.2.2. By Delivery
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Lyophilized Injectable Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Packaging
      • 6.3.2.2.2. By Delivery
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Lyophilized Injectable Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Packaging
      • 6.3.3.2.2. By Delivery
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By End-User

7. Europe Lyophilized Injectable Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Packaging
  • 7.2.2. By Delivery
  • 7.2.3. By Indication
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lyophilized Injectable Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Packaging
      • 7.3.1.2.2. By Delivery
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Lyophilized Injectable Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Packaging
      • 7.3.2.2.2. By Delivery
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Lyophilized Injectable Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Packaging
      • 7.3.3.2.2. By Delivery
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Lyophilized Injectable Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Packaging
      • 7.3.4.2.2. By Delivery
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Lyophilized Injectable Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Packaging
      • 7.3.5.2.2. By Delivery
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By End-User

8. Asia Pacific Lyophilized Injectable Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Packaging
  • 8.2.2. By Delivery
  • 8.2.3. By Indication
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lyophilized Injectable Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Packaging
      • 8.3.1.2.2. By Delivery
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Lyophilized Injectable Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Packaging
      • 8.3.2.2.2. By Delivery
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Lyophilized Injectable Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Packaging
      • 8.3.3.2.2. By Delivery
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Lyophilized Injectable Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Packaging
      • 8.3.4.2.2. By Delivery
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Lyophilized Injectable Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Packaging
      • 8.3.5.2.2. By Delivery
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Lyophilized Injectable Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Packaging
  • 9.2.2. By Delivery
  • 9.2.3. By Indication
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lyophilized Injectable Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Packaging
      • 9.3.1.2.2. By Delivery
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Lyophilized Injectable Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Packaging
      • 9.3.2.2.2. By Delivery
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Lyophilized Injectable Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Packaging
      • 9.3.3.2.2. By Delivery
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By End-User

10. South America Lyophilized Injectable Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Packaging
  • 10.2.2. By Delivery
  • 10.2.3. By Indication
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lyophilized Injectable Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Packaging
      • 10.3.1.2.2. By Delivery
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Lyophilized Injectable Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Packaging
      • 10.3.2.2.2. By Delivery
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Lyophilized Injectable Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Packaging
      • 10.3.3.2.2. By Delivery
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lyophilized Injectable Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. B. Braun Melsungen AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Baxter International Inc.
• 15.3. Becton, Dickinson and Company
• 15.4. Schott AG
• 15.5. Aristopharma Ltd.
• 15.6. Vetter Pharma GmbH
• 15.7. Jubilant HollisterStier LLC
• 15.8. F. Hoffmann-La Roche Ltd
• 15.9. Novo Nordisk A/S

16. Strategic Recommendations

17. About Us & Disclaimer